[Recent advances in the treatment of advanced breast cancer: therapeutic modalities at the National Cancer Center Hospital].
A retrospective analysis was performed comparing the survival in 483 patients with advanced breast cancer during the period from 1962 to 1986. Recently, the five-year survival rate at the start of therapy to the primary tumor was 63% and the five-year survival rate after the recurrence was 25%. The survival has been significantly prolonged as opposed to the figure of less than 5% among patients of 15 years ago. Multidisciplinary treatment has been utilized as adjuvant and recurrent therapies, such as combined chemotherapy, chemo-endocrine therapy and irradiation. Within these patients, 13 cases (3%) survived for more than ten-years from recurrence. The patients were recurrent cases with a small amount of metastatic sites and responsive to long-term endocrine therapy.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis
D000970:Antineoplastic Agents; D011960:Receptors, Estrogen